Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2

Conditions

Sarcoma 523Glioblastoma 179Gliosarcoma 178Osteosarcoma 155Dendritic Cell Sarcoma, Interdigitating 114Brain Neoplasms 113Gastrointestinal Stromal Tumors 108Central Nervous System Neoplasms 102Rhabdomyosarcoma 81Lymphoma 79Glioma 79Burkitt Lymphoma 79Lymphoma, Non-Hodgkin 78Recurrence 76Leiomyosarcoma 75Precursor Cell Lymphoblastic Leukemia-Lymphoma 73Lymphoma, Large B-Cell, Diffuse 70Liposarcoma 69Astrocytoma 68Sarcoma, Ewing 67Lymphoma, Follicular 63Neuroblastoma 60Lymphoma, Mantle-Cell 58Leukemia, Lymphocytic, Chronic, B-Cell 57Lymphoma, B-Cell, Marginal Zone 56Lymphoma, Large-Cell, Immunoblastic 54Hodgkin Disease 54Leukemia, Myeloid, Acute 53Neuroectodermal Tumors, Primitive, Peripheral 52Neoplasm Metastasis 51

Interventions

regorafenib 1envafolimab 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Piebaldism × Sarcoma × Clear all
NCT07559864 2026-04-30

Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment

Peking University Cancer Hospital & Institute

Phase 2 Recruiting
100 enrolled
GastrointestinalSarcoma

Piebaldism, Gastrointestinal Stromal Tumors

NCT00237185 2014-08-19

A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene

Novartis

Phase 2 Completed
148 enrolled 17 charts
GastrointestinalSarcoma

Piebaldism, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡